Moxifloxacin Kabi (Moxifloxacin Hydrochloride)

Moxifloxacin, the active ingredient in Moxifloxacin Kabi, is a fluoroquinolone antibiotic presented as an injectable solution for intravenous use. It is employed to treat serious bacterial infections, including respiratory, sinus, skin, and intra‑abdominal infections, in adult and pediatric patients as clinically indicated.

GNH USA supplies Moxifloxacin Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. Our distribution network ensures quality‑assured product delivery in compliance with global regulatory standards. We maintain rigorous temperature‑controlled logistics to preserve product integrity.

Moxifloxacin is a fluoroquinolone antibiotic used to treat bacterial infections in several organ systems.

- Community‑acquired pneumonia: effective bacterial eradication leading to clinical recovery. - Acute bacterial sinusitis: rapid resolution of sinus inflammation and infection. - Skin and soft tissue infections: eradication of causative pathogens and promotion of wound healing. - Intra‑abdominal infections: control of polymicrobial infection in the abdominal cavity.

Adverse reactions may occur with any antibacterial therapy. Monitoring for side effects is recommended.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: often self‑limiting watery stools. - Headache: transient cranial discomfort. - Rash: mild erythematous skin eruptions. - Elevated liver enzymes: transient increase in hepatic transaminases. - Transient QT interval prolongation: mild ECG changes without symptoms.

Serious or Rare Side Effects: - Tendon rupture or tendinitis: especially in the Achilles tendon. - Clostridioides difficile‑associated colitis: severe diarrhea and colitis. - Severe allergic reactions: anaphylaxis, angioedema. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: life‑threatening skin reactions. - Hepatic failure: marked elevation of liver enzymes and jaundice. - Cardiac arrhythmias: torsades de pointes associated with QT prolongation.

Use of Moxifloxacin requires careful assessment of patient‑specific factors. - Renal impairment: adjust dosing and monitor renal function. - Hepatic impairment: monitor liver enzymes and consider dose modification. - History of tendon disorders: avoid use due to risk of tendon rupture. - Concomitant QT‑prolonging drugs: perform ECG monitoring. - Pregnancy and lactation: prescribe only if benefits outweigh potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Moxifloxacin may interact with several drug classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Co‑administration with other fluoroquinolones: increased risk of cumulative toxicity. - Concurrent use with systemic anticoagulants: heightened bleeding risk. - Combination with other QT‑prolonging agents: potential for serious arrhythmias.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may augment central nervous system adverse effects. - Theophylline: possible increase in serum theophylline concentrations. - Corticosteroids: elevated risk of tendon rupture when used together.